Physician profile
Stephen Barman
NPI 1104185750
$1,499.39
in general payments reported to CMS, 2019-2025
16 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $84.95 · 2021: $11.92 · 2022: $113 · 2023: $51.80 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $645 · Education: $156 · Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $645.00 |
| Education | $156.48 |
| Food and Beverage | $149.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $645.00 | 2025 | Monjuvi |
| Gilead Sciences, INC. | $136.79 | 2019-2021 | |
| Amgen INC. | $90.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $88.05 | 2019-2025 | Imfinzi |
| Janssen Biotech, INC. | $87.99 | 2025 | Rybrevant |
| Seagen INC. | $84.95 | 2020 | |
| Pfizer INC. | $62.50 | 2019-2022 | |
| Abbvie INC. | $57.16 | 2025 | |
| Asd Specialty Healthcare, LLC | $48.32 | 2019 | |
| Astellas Pharma US INC | $46.03 | 2019-2025 | Padcev |
| Celgene Corporation | $39.46 | 2019-2025 | Breyanzi |
| Taiho Oncology, INC. | $32.15 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.17 | 2023 | Imbruvica |
| Merck Sharp & Dohme LLC | $23.63 | 2023 | Keytruda |
| Novartis Pharmaceuticals Corporation | $17.47 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Barman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.